{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:04:44Z","timestamp":1761059084686},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[1995,7,1]],"date-time":"1995-07-01T00:00:00Z","timestamp":804556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,6,28]]},"abstract":"<jats:title>SUMMARY<\/jats:title>\n               <jats:p>In this uncontrolled study 15 patients with ANCA-associated systemic vasculitis, who were poor responders to conventional therapy, were treated with single or multiple courses of intravenous immunoglobulin (IVIG), 30g\/day over 5 days. Clinical and serological evaluation was performed before and 4 weeks after IVIG. Six of the 15 patients experienced clinically significant benefit from IVIG. Improvement was confined to single organ manifestations (skin, ENT findings), no improvement was seen with conjunctivitis and scleritis, pericarditis or nephritis. No patient experienced complete remission after IVIG. Repeated courses of IVIG at 4-week intervals were no more effective than single courses. In six anti-proteinase 3 (PR3)-positive patients pretreatment sera were incubated with F(ab\u2032)2 fragments of the IVIG preparation in vitro to measure the inhibitory effect of IVIG on anti-PR3 activity. An inhibition of anti-PR3 activity by 25\u201370% was observed; this did not correlate with clinical effects. Approximately 40% of patients benefited from IVIG treatment, though complete remission of disease activity did not occur. Neither clinical characteristics nor the inhibitory effect of the IVIG preparation on serum anti-PR3 activity in vitro predicted clinical response to this treatment modality.<\/jats:p>","DOI":"10.1111\/j.1365-2249.1995.tb02268.x","type":"journal-article","created":{"date-parts":[[2010,7,26]],"date-time":"2010-07-26T18:10:01Z","timestamp":1280167801000},"page":"2-7","source":"Crossref","is-referenced-by-count":103,"title":["Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin"],"prefix":"10.1093","volume":"101","author":[{"given":"C","family":"RICHTER","sequence":"first","affiliation":[{"name":"Department of Rheumatology, University of L\u00fcbeck and Rheumaklinik Bad Bramstedt, L\u00fcbeck, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"SCHNABEL","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of L\u00fcbeck and Rheumaklinik Bad Bramstedt, L\u00fcbeck, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"CSERNOK","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of L\u00fcbeck and Rheumaklinik Bad Bramstedt, L\u00fcbeck, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"DE GROOT","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of L\u00fcbeck and Rheumaklinik Bad Bramstedt, L\u00fcbeck, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"REINHOLD-KELLER","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of L\u00fcbeck and Rheumaklinik Bad Bramstedt, L\u00fcbeck, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W L","family":"GROSS","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of L\u00fcbeck and Rheumaklinik Bad Bramstedt, L\u00fcbeck, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2008,6,28]]},"reference":[{"key":"2022011517510583400_b1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00002281-199401000-00003","article-title":"New developments in the treatment of systemic vasculitis","volume":"6","author":"Gross","year":"1994","journal-title":"Curr Opin Rheumatol"},{"key":"2022011517510583400_b2","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/art.1780370622","article-title":"Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis","volume":"37","author":"Reinhold-Keller","year":"1994","journal-title":"Arthritis Rheum"},{"key":"2022011517510583400_b3","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","article-title":"Wegener's granulomatosis: an analysis of 158 patients","volume":"116","author":"Hoffman","year":"1992","journal-title":"Ann Intern Med"},{"key":"2022011517510583400_b4","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","article-title":"High-dose intravenous gammaglobulin for idiotypic thrombocytopenic purpura in childhood","volume":"1","author":"Imbach","year":"1981","journal-title":"Lancet"},{"key":"2022011517510583400_b5","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/BF00918680","article-title":"Intravenous \u03b3-globulin in myasthenia gravis: interaction with anti-acetylcholine receptor autoantibodies","volume":"11","author":"Liblau","year":"1991","journal-title":"J Clin Immunol"},{"key":"2022011517510583400_b6","first-page":"603","article-title":"High dose immunoglobulin therapy in severe juvenile chronic arthritis: long-term follow-up in 16 patients","volume":"8","author":"Prieur","year":"1990","journal-title":"Clin Exp Rheumatol"},{"key":"2022011517510583400_b7","first-page":"91","article-title":"Intravenous immunoglobulin therapy for active, extensive, and medically refractory idiopatic ulcerative or Crohn's colitis","volume":"87","author":"Levine","year":"1992","journal-title":"Am J Gastroenterol"},{"key":"2022011517510583400_b8","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0002-9343(91)90009-M","article-title":"Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients","volume":"91","author":"Cherin","year":"1991","journal-title":"Am J Med"},{"key":"2022011517510583400_b9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF00918189","article-title":"Intravenous immunoglobulin (IVIG) for the therapy of autoimmune disorders","volume":"10","author":"Schwartz","year":"1990","journal-title":"J Clin Immunol"},{"key":"2022011517510583400_b10","doi-asserted-by":"crossref","first-page":"476","DOI":"10.7326\/0003-4819-120-6-199403150-00005","article-title":"High-dose immunoglobulin therapy for severe IgA nephropathy and Henoch-Sch\u00f6nlein purpura","volume":"120","author":"Rostoker","year":"1994","journal-title":"Ann Intern Med"},{"key":"2022011517510583400_b11","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJM198608073150601","article-title":"The treatment of Kawasaki syndrome with intravenous gamma globulin","volume":"315","author":"Newburgher","year":"1986","journal-title":"N Engl J Med"},{"key":"2022011517510583400_b12","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/0090-1229(89)90082-2","article-title":"Intravenous gammaglobulin therapy in systemic lupus erythematosus and immune complex disease","volume":"53","author":"Jordan","year":"1989","journal-title":"Clin Immunol Immunopathol"},{"key":"2022011517510583400_b13","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/0140-6736(91)92797-6","article-title":"Treatment of systemic vasculitis with pooled intravenous immunoglobulin","volume":"337","author":"Jayne","year":"1991","journal-title":"Lancet"},{"key":"2022011517510583400_b14","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/978-1-4757-9182-2_84","article-title":"Pooled intravenous immunoglobulin in the management of systemic vasculitis","volume-title":"ANCA-associated vasculitides","author":"Jayne","year":"1993"},{"key":"2022011517510583400_b15","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1006\/jaut.1993.1018","article-title":"ANCA anti-idiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin","volume":"6","author":"Jayne","year":"1993","journal-title":"J Autoimmun"},{"key":"2022011517510583400_b16","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/art.1780330807","article-title":"The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis","volume":"33","author":"Leavitt","year":"1990","journal-title":"Arthritis Rheum"},{"key":"2022011517510583400_b17","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/art.1780370206","article-title":"Nomenclature of systemic vasculitides. Proposal of an international consensus conference","volume":"37","author":"Jennette","year":"1994","journal-title":"Arthritis Rheum"},{"key":"2022011517510583400_b18","first-page":"777","article-title":"Wegener's granulomatosis: anatomic correlates, a proposed classification","volume":"51","author":"DeRemee","year":"1976","journal-title":"Mayo Clin Proc"},{"key":"2022011517510583400_b19","first-page":"15","article-title":"Wegener's granulomatosis: new aspects of the disease course, immunodiagnostic procedures, and stage adapted treatment","volume":"6","author":"Gross","year":"1989","journal-title":"Sarcoidosis"},{"key":"2022011517510583400_b20","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1007\/BF01718027","article-title":"Stage adapted treatment of Wegener's granulomatosis","volume":"67","author":"Steppat","year":"1989","journal-title":"Klin Wochenschr"},{"key":"2022011517510583400_b21","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/art.1780350914","article-title":"Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis","volume":"35","author":"Schmitt","year":"1992","journal-title":"Arthritis Rheum"},{"key":"2022011517510583400_b22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.7326\/0003-4819-111-1-28","article-title":"Anti-cytoplasmic antibodies: their immunodiagnostic value in Wegener's granulomatosis","volume":"111","author":"N\u00f6lle","year":"1989","journal-title":"Ann Intern Med"},{"key":"2022011517510583400_b23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.1993.tb03345.x","article-title":"ANCA and associated diseases: immunodiagnostic and pathogenetic aspects","volume":"91","author":"Gross","year":"1993","journal-title":"Clin Exp Immunol"},{"key":"2022011517510583400_b24","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1084\/jem.171.1.357","article-title":"Anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis recognize an elastinolytic enzyme","volume":"171","author":"L\u00fcdemann","year":"1990","journal-title":"J Exp Med"},{"key":"2022011517510583400_b25","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/227680a0","article-title":"Cleavage of structural proteins during the assembly of the head of bacteriophage T4","volume":"227","author":"Laemmli","year":"1970","journal-title":"Nature"},{"key":"2022011517510583400_b26","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1365-2249.1991.tb05631.x","article-title":"Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis","volume":"83","author":"Rossi","year":"1991","journal-title":"Clin Exp Immunol"},{"key":"2022011517510583400_b27","first-page":"82","article-title":"Cellular changes during the infusion of high dose intravenous immunoglobulin","volume":"59","author":"Newland","year":"1989","journal-title":"Blood"},{"key":"2022011517510583400_b28","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/1097-0142(19910915)68:6+<1430::AID-CNCR2820681405>3.0.CO;2-4","article-title":"Mechanisms of action of intravenous immunoglobulin therapy and potential use in autoimmune connective tissue diseases","volume":"68","author":"Ballow","year":"1991","journal-title":"Cancer"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2249.1995.tb02268.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/101\/1\/2\/42202669\/j.1365-2249.1995.tb02268.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/101\/1\/2\/42202669\/j.1365-2249.1995.tb02268.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T18:04:39Z","timestamp":1642269879000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/101\/1\/2\/6484145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,7]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2008,6,28]]},"published-print":{"date-parts":[[2008,6,28]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2249.1995.tb02268.x","relation":{},"ISSN":["1365-2249","0009-9104"],"issn-type":[{"value":"1365-2249","type":"electronic"},{"value":"0009-9104","type":"print"}],"subject":[],"published-other":{"date-parts":[[1995,7]]},"published":{"date-parts":[[1995,7]]}}}